Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Sex Differences in the Use of Statins in Community Practice
Wang, Tracy Y., Xiang, Qun, Goldberg, Anne C. , Robinson, Jennifer G. , Roger, Véronique L. , Louie, Michael J. , Koren, Andrew , Li, Zhuokai , Nanna, Michael G. , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 16, 2019 | Volume: 12 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.118.005562 | PMID 31416347 Get It

Background: Female patients have historically received less aggressive lipid management than male patients. Contemporary care patterns and the potential causes for these differences are unknown. Methods and Results: Examining the Patient and Provider Assessment of Lipid Management Registry—a nationwide registry of outpatients with or at risk for atherosclerotic cardiovascular disease—we compared the use of statin therapy, guideline-recommended statin dosing, and reasons for undertreatment. We specifically analyzed sex differences in statin treatment and guideline-recommended statin dosing using multivariable logistic regression. Among 5693 participants (43% women) eligible for 2013 American College of Cardiology/American Heart Association Cholesterol Guideline–recommended statin treatment, women were less likely than men to be prescribed any statin therapy (67.0% versus 78.4%; P <0.001) or to receive a statin at the guideline-recommended intensity (36.7% versus 45.2%; P <0.001). Women were more likely to report having previously never been offered statin therapy (18.6% versus 13.5%; P <0.001), declined statin therapy (3.6% versus 2.0%; P <0.001), or discontinued their statin (10.9% versus 6.1%; P <0.001). Women were also less likely than men to believe statins were safe (47.9% versus 55.2%; P <0.001) or effective (68.0% versus 73.2%; P <0.001) and more likely to report discontinuing their statin because of a side effect (7.9% versus 3.6%; P <0.001). Sex differences in both overall and guideline-recommended intensity statin use persisted after adjustment for demographics, socioeconomic factors, clinical characteristics, patient beliefs, and provider characteristics (adjusted odds ratio, 0.70; 95% CI, 0.61–0.81; P <0.001; and odds ratio, 0.82; 95% CI, 0.73–0.92; P <0.01, respectively). Sex differences were consistent across primary and secondary prevention indications for statin treatment. Conclusions: Women eligible for statin therapy were less likely than men to be treated with any statin or guideline-recommended statin intensity. A combination of women being offered statin therapy less frequently, while declining and discontinuing treatment more frequently, accounted for these sex differences in statin use.
Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant
Puffer, Ross C. , Spinner, Robert J. , Bi, Hong‐Yan , Sharma, Rishi , Theis, Jason D. , Poterucha, John J., Bi, Hongyan, Bi, Hongyan, Wang, Yucai , McPhail, Ellen Darcy , Niu, Zhiyv , Klein, Christopher J.

Mayo Clinic

Neurology Genetics | August 15, 2019 | Volume: 5 | Issue: 5 | Pages: No page available

10.1212/nxg.0000000000000351 | PMID 31517060 Get It

Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples
Bhagwate, Aditya , Liu, Yuanhang , McDonough, Samantha J., Heinzen, Ethan P. , Frost, Marlene H., Cunningham, Julie M. , Winham, Stacey J. , Stallings‐Mann, Melody , Davila, Jaime , Vierkant, Robert A. , Hoskin, Tanya L. , Carter, Jodi M. , Radisky, Derek C. , Degnim, Amy C. , Wang, Chen

Mayo Clinic

No container title available | August 13, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.9892/v2 Get It

Abstract Background Archived formalin fixed paraffin embedded (FFPE) samples are valuable clinical resources to examine clinically relevant morphology features and also to study genetic changes. However, DNA quality and quantity of FFPE samples are often sub-optimal, and resulting NGS-based genetics variant detections are prone to false positives. Evaluations of wet-lab and bioinformatics approaches are needed to optimize variant detection from FFPE samples. Results As a pilot study, we designed within-subject triplicate samples of DNA derived from paired FFPE and fresh frozen breast tissues to highlight FFPE-specific artifacts. For FFPE samples, we tested two FFPE DNA extraction methods to determine impact of wet-lab procedures on variant calling: QIAGEN QIAamp DNA Mini Kit ("QA"), and QIAGEN GeneRead DNA FFPE Kit ("QGR"). We also used negative-control (NA12891) and positive control samples (Horizon Discovery Reference Standard FFPE). All DNA sample libraries were prepared for NGS according to the QIAseq Human Breast Cancer Targeted DNA Panel protocol and sequenced on the HiSeq 4000. Variant calling and filtering were performed using QIAGEN Gene Globe Data Portal. Detailed variant concordance comparisons and mutational signature analysis were performed to investigate effects of FFPE samples compared to paired fresh frozen samples, along with different library preparations. In this study, we found that five times or more variants were called with FFPE samples, compared to their paired fresh-frozen tissue samples even after applying molecular barcoding error-correction and default bioinformatics filtering recommended by the vendor. We also found that QGR as an optimized FFPE-DNA extraction approach leads to much fewer discordant variants between paired fresh frozen and FFPE samples. Approximately 92% of the uniquely called FFPE variants were of low allelic frequency range (<5%), and collectively shared a “C>T|G>A” mutational signature known to be representative of FFPE artifacts resulting fromcytosine deamination. Based on control samples and FFPE-frozen replicates, we derived an effective filtering strategy with associated empirical false-discovery estimates. Conclusions Through this study, we demonstrated feasibility of calling and filtering genetic variants from FFPE tissue samples using a combined strategy with molecular barcodes, optimized DNA extraction, and bioinformatics methods incorporating genomics context such as mutational signature and variant allelic frequency.
Performance evaluation of computed tomography systems: Summary of AAPM Task Group 233
Bakalyar, Donovan, Boedeker, Kirsten , Fan, Jiahua , Myers, Kyle J. , Popescu, Lucreţiu M. , Giraldo, Juan Carlos Ramírez, Ranallo, Frank N. , Solomon, Justin , Vaishnav, J. Y., Wang, Jia , Samei, Ehsan , Brady, Samuel L. , Leng, Shuai , Vaishnav, Jay

Mayo Clinic

Medical Physics | August 13, 2019 | Volume: 46 | Issue: 11 | Pages: No page available

10.1002/mp.13763 | PMID 31408540 Get It

Background The rapid development and complexity of new x‐ray computed tomography (CT) technologies and the need for evidence‐based optimization of image quality with respect to radiation and contrast media dose call for an updated approach towards CT performance evaluation. Aims This report offers updated testing guidelines for testing CT systems with an enhanced focus on the operational performance including iterative reconstructions and automatic exposure control (AEC) techniques. Materials and Methods The report was developed based on a comprehensive review of best methods and practices in the scientific literature. The detailed methods include the assessment of 1) CT noise (magnitude, texture, nonuniformity, inhomogeneity), 2) resolution (task transfer function under varying conditions and its scalar reflections), 3) task‐based performance (detectability, estimability), and 4) AEC performance (spatial, noise, and mA concordance of attenuation and exposure modulation). The methods include varying reconstruction and tube current modulation conditions, standardized testing protocols, and standardized quantities and metrology to facilitate tracking, benchmarking, and quantitative comparisons. Results The methods, implemented in cited publications, are robust to provide a representative reflection of CT system performance as used operationally in a clinical facility. The methods include recommendations for phantoms and phantom image analysis. Discussion In line with the current professional trajectory of the field toward quantitation and operational engagement, the stated methods offer quantitation that is more predictive of clinical performance than specification‐based approaches. They can pave the way to approach performance testing of new CT systems not only in terms of acceptance testing (i.e., verifying a device meets predefined specifications), but also system commissioning (i.e., determining how the system can be used most effectively in clinical practice). Conclusion We offer a set of common testing procedures that can be utilized towards the optimal clinical utilization of CT imaging devices, benchmarking across varying systems and times, and a basis to develop future performance‐based criteria for CT imaging.
Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes
Din, Lennox, Kosaraju, Nikitha , Smedby, Karin E. , Berndt, Sonja I. , Skibola, Christine F., Nieters, Alexandra, Wang, Sophia , McKay, James , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Mack, Thomas M. , Sanjosé, Sílvia de , Vyse, Timothy J. , Padyukov, Leonid , Monnereau, Alain , Arslan, Alan A. , Moore, Amy , Brooks‐Wilson, Angela , Novak, Anne J. , Glimelius, Bengt , Birmann, Brenda M. , Link, Brian K. , Stewart, Carolyn, Vajdic, Claire M. , Magnani, Corrado , Conti, David V. , Cox, David G. , Casabonne, Delphine, Kane, Eleanor , Roman, Eve , Salles, Gilles , Adami, Hans‐Olov , Ghesquières, Hervé , Vivo, Immaculata De , Clavel, Jacqueline , Spinelli, John J., Curtin, Karen , Costenbader, Karen H. , Onel, Kenan , Offit, Kenneth , Morton, Lindsay M. , Conde, Lucía , Miligi, Lucia , Melbye, Mads , Liebow, Mark , Purdue, Mark P. , Glenn, Martha, Din, M. Azhar Ud, Rothman, Nathaniel , Camp, Nicola J. , Doo, Nicole Wong , Becker, Nikolaus, Pradhan, Nisha , Bracci, Paige M. , Vineis, Paolo , Brennan, Paul , Kraft, Peter , Lan, Qing , Severson, Richard K., Vermeulen, Roel , Kaaks, Rudolph, Travis, Ruth C. , Weinstein, Stephanie J. , Ansell, Stephen M. , Zheng, Tongzhang, Benavente, Yolanda , Taub, Zachary, Madireddy, Lohith, Gourraud, Pierre‐Antoine , Oksenberg, Jorge R. , Hjalgrim, Henrik , Khankhanian, Pouya , Cerhan, James R , Khankhanian, Pouya , Link, Brian K , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , De Vivo, Immaculata , Kraft, Peter , Morton, Lindsay M , Padyukov, Leonid , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Conti, David V , Doo, Nicole Wong , Sheikh, Mohammad, Bernatsky, Sasha , Maynadié, Marc , Haïoun, Corinne , Casabonne, Delphine , Albanes, Demetrius , Muzi, Giacomo , Giles, Graham G. , Cerhan, James R. , Hofmann, Jonathan N. , Vijai, Joseph , Teras, Lauren R. , Ennas, Maria Grazia , Southey, Melissa C. , Boffetta, Paolo , Milne, Roger L. , Chanock, Stephen Jacob , Slager, Susan L. , Zhang, Yawei , Cozen, Wendy

Mayo Clinic

Genetic Epidemiology | August 13, 2019 | Volume: 43 | Issue: 7 | Pages: 844-863

10.1002/gepi.22242 | PMID 31407831 Get It

AbstractEpidemiologic studies show an increased risk of non‐Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen‐stimulation in one disease leads to another. Here we assess shared genetic risk in genome‐wide‐association‐studies (GWAS).Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B‐cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta‐analysis.Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta‐analysis (combing AD with NHL) implicated genes of apoptosis and telomere length.This GWAS‐based analysis four NHL subtypes and three ADs revealed few weakly‐associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.
TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM)
Northfelt, Donald W. , Cynthia, X. , Maxwell, Fiona , Wang, Tiffany , Belanger, Bruce , Moore, Yan , Sachdev, Jasgit C. , Anders, Carey K. , Münster, Pamela N. , Han, Hyo S , Zhang, Bin

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i9-i9

10.1093/noajnl/vdz014.039 Get It

Abstract BACKGROUND: nal-IRI is a liposomal formulation of irinotecan (topoisomerase-1 inhibitor). Preclinical data show that nal-IRI accumulates in BMs and prolongs survival in animal models of BM. Findings from a phase 1 expansion study (NCT01770353), evaluating patients with mBC and active BM, are reported. METHODS: This phase 1 expansion study enrolled patients with mBC who received multiple prior lines of cytotoxic therapy in the metastatic setting, including one cohort with mBC and active BM, defined as radiographic evidence of new or progressive central nervous system (CNS) metastases after radiation therapy with ≥1 lesion of ≥1 cm in the longest dimension on gadolinium-enhanced magnetic resonance imaging. Patients received nal-IRI 50 mg/m2 (free-base equivalent; FBE) every two weeks (q2w) as an intravenous infusion over 90 minutes, escalating to 70 mg/m2 FBE q2w, if tolerated. RECIST v1.1 and modified RECIST criteria were used to assses non-CNS and CNS disease, respectively. RESULTS: In total, 30 patients were enrolled (10 with active BM). Median age was 53 years (range 29–70 years) and median number of prior cytotoxic anti-cancer regimens was 3 (range 0–6); 29 patients received ≥1 dose of nal-IRI 50 mg/m2 FBE. Overall, nal-IRI monotherapy appeared to be well tolerated, and achieved ≥30% objective response rates for both CNS and non-CNS disease. Among the 10 patients with active BM, 6 achieved CNS disease control (3 partial responses [PRs] and 3 stable disease [SD]), including one patient with durable CNS SD and non-CNS PR for 2 years. Among 7 patients with serial evaluation of CNS metastases posttreatment, 6 patients achieved a reduction in target CNS lesions compared with baseline. CONCLUSION: Treatment with nal-IRI resulted in CNS disease control among 6 of 10 heavily pretreated patients with mBC and active BM. Further exploration of nal-IRI in patients with mBC and active BM is warranted.
THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR
Wang, Shen , Bacha, Jeffrey , Brown, Dennis , Kanekal, Sarath, Wang, ZhenZhong, Pedersen, Harry, Butowski, Nicholas , James, C. David , Sankar, Neil , Nicolaides, Theodore , Sarkaria, Jann N. , Giles, Francis Joseph

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i10-i11

10.1093/noajnl/vdz014.044 Get It

Abstract Dysregulation of ErbB-mediated signaling is observed in up to 90% of solid tumors. ErbB family cross-talk is implicated in the development of resistance and metastasis, including CNS metastases. Inhibition of multiple ErbB receptors may result in improved patient outcomes. EO1001 is a novel, patented, oral, brain-penetrating, irreversible pan-ErbB inhibitor targeting EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4). METHODS: (1) In vitro testing. EO1001 demonstrates high specificity for the ErbB family of receptors with excellent, balanced equipotent activity against EGFR, HER2 and HER4 (0.4 to 7.4 nM). EO1001 inhibits signaling downstream of wild type EGFR, mutant EGFR (T790M, L858R and d746-750) and HER2. (2) PK and toxicity. In rodent studies in vivo, EO1001 exhibited a half-life of 16–20 hours. EO1001 rapidly enters the CNS and penetrates tumor tissue at higher concentrations relative to plasma. Safety of EO1001 was evaluated by repeat-dosing studies in SD rats and beagle dogs. Toxicities typical of the ErbB inhibitor class, including gastro-intestinal effects, weight loss and decreased activity were observed at higher dose groups in both species. Mortality was observed in SD rats at higher dose groups. (3) In vivo efficacy studies. EO1001 was studied following oral administration in several erbB-positive mouse xenograft models including N87 (Her2+), H1975 (EGFR/T790M), GBM12 (EGFR+), GBM39 (EGVRvIII+). Following oral administration, treatment with EO1001 resulted in a statistically significant improvement in outcomes compared to positive and negative controls in both CNS and systemic tumor models. EO1001 was well-tolerated with no gastrointestinal side effects observed at efficacious doses in these models. CONCLUSION: Based on research to date, EO1001 has the potential to be a best-in-class CNS-penetrating pan-ErbB inhibitor with a safety and pharmacokinetic profile amenable for use as a single agent and in combination with other agents. EO1001 is poised to enter phase 1-2a clinical testing in the second-half of 2019.
Alternating EM algorithm for a bilinear model in isoform quantification from RNA-seq data
Deng, Wenjiang , Mou, Tian , Niu, Nifang, Wang, Liewei , Vu, Trung Nghia , Kalari, Krishna R. , Pawitan, Yudi

Mayo Clinic

Bioinformatics | August 9, 2019 | Volume: 36 | Issue: 3 | Pages: 805-812

10.1093/bioinformatics/btz640 | PMID 31400221 Get It

Abstract Motivation Estimation of isoform-level gene expression from RNA-seq data depends on simplifying assumptions, such as uniform read distribution, that are easily violated in real data. Such violations typically lead to biased estimates. Most existing methods provide bias correction step(s), which is based on biological considerations—such as GC content—and applied in single samples separately. The main problem is that not all biases are known. Results We have developed a novel method called XAEM based on a more flexible and robust statistical model. Existing methods are essentially based on a linear model Xβ, where the design matrix X is known and is computed based on the simplifying assumptions. In contrast XAEM considers Xβ as a bilinear model with both X and β unknown. Joint estimation of X and β is made possible by a simultaneous analysis of multi-sample RNA-seq data. Compared to existing methods, XAEM automatically performs empirical correction of potentially unknown biases. We use an alternating expectation-maximization (AEM) algorithm, alternating between estimation of X and β. For speed XAEM utilizes quasi-mapping for read alignment, thus leading to a fast algorithm. Overall XAEM performs favorably compared to recent advanced methods. For simulated datasets, XAEM obtains higher accuracy for multiple-isoform genes. In a differential-expression analysis of a real single-cell RNA-seq dataset, XAEM achieves substantially better rediscovery rates in independent validation sets. Availability and implementation The method and pipeline are implemented as a tool and freely available for use at http://fafner.meb.ki.se/biostatwiki/xaem/. Supplementary information Supplementary data are available at Bioinformatics online.
Glaucoma Drainage Devices and Reasons For Keratoplasty
Knier, Kit , Wang, Feng, Baratz, Keith H. , Khanna, Cheryl L. , Knier, Catherine G, Baratz, Keith

Mayo Clinic

Journal of Glaucoma | August 8, 2019 | Volume: 28 | Issue: 10 | Pages: 906-910

10.1097/ijg.0000000000001340 | PMID 31393312 Get It

Précis: Over 10 years in a tertiary care setting, glaucoma drainage devices (GDDs) have not increased as a reason for keratoplasty. Purpose: The purpose of this study was to determine whether the reasons for keratoplasty have changed between 10 years in a tertiary care setting, with special attention to the rate of GDDs as a reason for keratoplasty. Methods: Patients aged 18 years or above who underwent keratoplasty at Mayo Clinic, Rochester, MN from 2005 to 2006 and 2015 to 2016 were studied. All reasons for keratoplasty performed in the study time period are assessed, including patients who previously had a GDD implanted in the same eye. After analyzing the reasons for keratoplasty, we assess whether the reasons for keratoplasty have changed between 2005 to 2006 and 2015 to 2016 in association with the increasing placement of GDDs. Results: The number of keratoplasty procedures performed in the 2 time periods increased by 62% from 163 (2005 to 2006) to 264 (2015 to 2016), whereas GDD placement increased by 164% from 80 GDD (2005 to 2006) to 211 GDD (2015 to 2016). Although the performance of keratoplasty increased between the 2 points in time, the frequency of each cause for keratoplasty did not change significantly. The majority of keratoplasties were performed due to corneal disease, and GDDs made up a small portion of reasons for keratoplasty (2005 to 2006, 4.29%; 2015 to 2016, 5.68%). Conclusions: The frequency of GDDs as a reason for keratoplasty has not changed significantly between 10 years in this tertiary care setting. Patients with GDDs who later required keratoplasty had associated features including multiple surgical procedures and comorbid infection, pseudophakic bullous keratopathy, Fuchs dystrophy, pseudoexfoliation, uveitis, and congenital glaucoma.
Abstract 2980: The role of USP7 and USP7 inhibitor in HER2+ breast cancer treatment
Yu, Jia , Qin, Bo , Wang, Liewei , Boughey, Judy C. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 2980-2980

10.1158/1538-7445.am2019-2980 Get It

Abstract INTRODUCTION: Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women. Approximately 20% of breast cancer tumors overexpress human epidermal growth factor receptor 2 (HER2), which is associated with an aggressive clinical phenotype and with a poorer prognosis. The development of trastuzumab, an immunoglobulin G monoclonal antibody directed against HER2, has changed the treatment paradigm for this disease. However, approximately 15-20% still does not respond to anti-HER2 therapy. Furthermore, despite advances in the management of metastatic HER2-positive breast cancer, response rate varies greatly, with most patients eventually succumbing to their disease. It is crucial to develop additional therapeutic strategies to improve outcomes for HER2 positive patients, especially those with tumors that do not respond to anti-HER2 therapy. METHODS and RESULTS: Using HER2+ breast cancer cell lines, we found that an USP7 inhibitor, P5091, dramatically sensitized cancer cells to HER2 inhibitor, trastuzumab treatment. To confirm it in vivo, we tested the drug combination in BT474 xenografts and found P5091 and trastuzumab synergistically suppressed tumor growth. Furthermore, using trastuzumab resistant HER2+ breast cancer cell line, we found that USP7 inhibitor, P5091, can dramatically re-sensitize trastuzumab-resistant BT474 cell line to trastuzumab treatment both in vitro and in vivo. More importantly, using patient derived xenograft (PDX) HER2+ models, we confirmed the synergistic combination effect of P5091 and trastuzumab. Mechanistically, USP7 inhibitor, P5091 led to significantly increased degradation of all four HER family members (HER1-4). When we knocked down USP7 by RNA interference or small hairpin RNA (shRNA), we observed similar substantial decrease in HER family member proteins. CONCLUSIONS: We have demonstrated the feasibility of using USP7 inhibitor P5091 to sensitize HER2+ breast cancers to trastuzumab treatment. These results provide a rationale for the use of combination therapy of USP7 inhibitors and HER2 inhibitors to treat HER2+ breast cancer. This combination therapy might also be effective in other cancers with upregulated HER signaling, such as GI cancer, lung cancer or ovarian cancer. Citation Format: Jia Yu, Bo Qin, Judy Boughey, Matthew Goetz, Liewei Wang. The role of USP7 and USP7 inhibitor in HER2+ breast cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2980.